Satellos Bioscience Inc. has made a significant advancement by securing a composition of matter patent for its lead drug candidate, forazapadin. The U.S. Patent and Trademark Office issued U.S. Patent No. 12,747,245, which covers forazapadin and a broader class of AAK1 inhibitors. This patent is crucial as it provides intellectual property protection until September 6, 2044, allowing Satellos to strengthen its position in the competitive pharmaceutical industry.
Frank Gleeson, co-founder and CEO of Satellos, emphasized the importance of this patent, stating, "The issuance of this composition of matter patent represents a significant advancement for Satellos and supports our long-term development and commercialization strategy for the program." The patent reinforces the novelty of Satellos' approach to restoring muscle regeneration, which is vital for its ongoing clinical trials.
Background
Satellos Bioscience Inc. is a clinical-stage drug development company focused on creating innovative medicines for degenerative muscle diseases. The company operates under the Standard Industrial Classification (SIC) 2834, which pertains to pharmaceutical preparations. It is publicly traded on the Nasdaq under the ticker symbol MSLE.
What the Filing Says
The filing dated October 5, 2026, indicates that the patent provides coverage for forazapadin as well as a broader class of AAK1 inhibitors. The company plans to seek a Patent Term Extension following future U.S. marketing approval, potentially extending the patent protection beyond the current expiration date.
Impact
This patent may significantly affect Satellos' ability to advance forazapadin in clinical trials for conditions such as Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). The protection afforded by the patent strengthens Satellos' intellectual property estate, which is crucial for attracting investment and partnerships in the pharmaceutical sector.
What's Next
Following the patent approval, Satellos intends to seek to have this patent listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, after potential U.S. marketing approval of forazapadin. The filing does not specify what happens next.